MRT-2359   Click here for help

GtoPdb Ligand ID: 12629

Synonyms: MRT2359
Compound class: Synthetic organic
Comment: MRT-2359 is a GSPT1 (a.k.a. eRF3a)-targeting molecular glue degrader. It uses a cereblon (CRBN) binding moiety to induce degradation of the translation termination factor GSPT1 (GSPT1; P15170). The degrader was developed to target MYC-driven tumours that are thought to become dependent on GSPT1. MRT-2359 induces an anti-proliferative effect on cancer cells.
The chemical structure for MRT-2359 was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.

MRT-2359 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 114.04
Molecular weight 495.38
XLogP 0.86
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=C(C=C2C(=C1)CN(C3CCC(=O)NC3=O)C2=O)COC(=O)NC4=CC(=CC=C4F)OC(F)(F)F
Isomeric SMILES FC1=CC=C(OC(F)(F)F)C=C1NC(=O)OCC2=CC3=C(CN(C4CCC(=O)NC4=O)C3=O)C=C2
InChI InChI=1S/C22H17F4N3O6/c23-15-4-3-13(35-22(24,25)26)8-16(15)27-21(33)34-10-11-1-2-12-9-29(20(32)14(12)7-11)17-5-6-18(30)28-19(17)31/h1-4,7-8,17H,5-6,9-10H2,(H,27,33)(H,28,30,31)
InChI Key HNTGMIGBGVFOBT-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
MRT-2359 has advanced to clinical evaluation, for efficacy against advanced solid tumours. In 2025, the developer (Monte Rosa Therapeutics) decided to focus development of MRT-2359 in prostate cancer, for which there was the most clear evidence of L- or N-MYC expression in the tumour tissue.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05546268 Study of Oral MRT-2359 in Selected Cancer Patients Phase 1/Phase 2 Interventional Monte Rosa Therapeutics, Inc